{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:11:15Z","timestamp":1793452275008,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,7,10]],"date-time":"2015-07-10T00:00:00Z","timestamp":1436486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.joca.2015.07.001","type":"journal-article","created":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T20:11:08Z","timestamp":1436904668000},"page":"2086-2093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement"],"prefix":"10.1016","volume":"23","author":[{"given":"J.-Y.","family":"Reginster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Reiter-Niesert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Berenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-L.","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Devogelaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Herrero-Beaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Maheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Richette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joca.2015.07.001_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ard.2003.009613","article-title":"Degenerative musculoskeletal disease","volume":"63","author":"Ethgen","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.07.001_bib2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2014.05.014","article-title":"An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)","volume":"44","author":"Bruyere","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.joca.2015.07.001_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0140-6736(00)03610-2","article-title":"Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial","volume":"357","author":"Reginster","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.joca.2015.07.001_bib4","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1001\/archinte.162.18.2113","article-title":"Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study","volume":"162","author":"Pavelka","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.joca.2015.07.001_bib5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/art.24255","article-title":"Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial","volume":"60","author":"Kahan","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2015.07.001_bib6","series-title":"Points to Consider on Clinical Investigation of Medicinal Products Used in Treatment of Osteoarthritis","author":"CPMP","year":"1998"},{"key":"10.1016\/j.joca.2015.07.001_bib7","unstructured":"European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Medicinal Products for Human Use (CHMP), Committee for Proprietary Medicinal Products (CPMP). Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. -14. 20-1-2010. London. Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis."},{"key":"10.1016\/j.joca.2015.07.001_bib8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/ard.55.8.552","article-title":"Recommendations for the registration of drugs used in the treatment of osteoarthritis. Group for the respect of ethics and excellence in science (GREES): osteoarthritis section","volume":"55","author":"Dougados","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.07.001_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/joca.2000.0387","article-title":"Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers","volume":"9","author":"Vignon","year":"2001","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2015.07.001_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.joca.2004.01.006","article-title":"Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis","volume":"12","author":"Abadie","year":"2004","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2015.07.001_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.joca.2004.10.012","article-title":"Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis","volume":"13","author":"Altman","year":"2005","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2015.07.001_bib12","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1002\/art.27694","article-title":"Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study","volume":"62","author":"Baerwald","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2015.07.001_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1533-2500.2010.00401.x","article-title":"A\u00a0double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee","volume":"11","author":"Chappell","year":"2011","journal-title":"Pain Pract"},{"key":"10.1016\/j.joca.2015.07.001_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/acr.21596","article-title":"American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee","volume":"64","author":"Hochberg","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.joca.2015.07.001_bib15","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.3899\/jrheum.130192","article-title":"A\u00a0randomized, double-blind, phase III trial in moderate osteoarthritis knee pain comparing topical ketoprofen gel with ketoprofen-free gel","volume":"40","author":"Rother","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2015.07.001_bib16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.joca.2009.12.013","article-title":"Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study","volume":"18","author":"Schnitzer","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2015.07.001_bib17","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/bmj.38273.626655.63","article-title":"Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials","volume":"329","author":"Bjordal","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.joca.2015.07.001_bib18","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/ard.2003.015974","article-title":"Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib","volume":"63","author":"Tannenbaum","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.07.001_bib19","first-page":"21","article-title":"Efficacy of lumiracoxib in osteoarthritis: a review of nine studies","volume":"33","author":"Berenbaum","year":"2005","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.joca.2015.07.001_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejpain.2006.02.013","article-title":"Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials","volume":"11","author":"Bjordal","year":"2007","journal-title":"Eur J Pain"},{"key":"10.1016\/j.joca.2015.07.001_bib21","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.joca.2013.04.018","article-title":"Mechanisms of the placebo response in pain in osteoarthritis","volume":"21","author":"Abhishek","year":"2013","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2015.07.001_bib22","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1136\/ard.2008.092015","article-title":"The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials","volume":"67","author":"Zhang","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.07.001_bib23","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/ard.2008.097006","article-title":"The art of medicine in treating osteoarthritis: I will please","volume":"67","author":"Bijlsma","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.07.001_bib24","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy","year":"1988","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2015.07.001_bib25","first-page":"2635","article-title":"Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis","volume":"27","author":"Ehrich","year":"2000","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2015.07.001_bib26","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1185\/03007995.2013.792793","article-title":"How to define responders in osteoarthritis","volume":"29","author":"Cooper","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.joca.2015.07.001_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard.2004.022905","article-title":"Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement","volume":"64","author":"Tubach","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.07.001_bib28","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/acr.21747","volume":"64","author":"Tubach","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.joca.2015.07.001_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/ard.2004.023028","article-title":"Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state","volume":"64","author":"Tubach","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.07.001_bib30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.joca.2004.02.001","article-title":"OMERACT-OARSI initiative: osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited","volume":"12","author":"Pham","year":"2004","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2015.07.001_bib31","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.joca.2010.04.005","article-title":"Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: a meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Trijau","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2015.07.001_bib32","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3899\/jrheum.100743","article-title":"Consistency of knee pain and risk of knee replacement: the Multicenter Osteoarthritis Study","volume":"38","author":"Wise","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2015.07.001_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.joca.2011.11.013","article-title":"OARSI-OMERACT initiative: defining thresholds for symptomatic severity and structural changes in disease modifying osteoarthritis drug (DMOAD) clinical trials","volume":"20","author":"Manno","year":"2012","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2015.07.001_bib34","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Points to consider on multiplicity issues in clinical trials. 19-9-2002."},{"key":"10.1016\/j.joca.2015.07.001_bib35","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jbspin.2006.09.008","article-title":"Symptomatic slow-acting drugs for osteoarthritis: what are the facts?","volume":"73","author":"Dougados","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.joca.2015.07.001_bib36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2474-9-165","article-title":"Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system","volume":"9","author":"Bruyere","year":"2008","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.joca.2015.07.001_bib37","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1503\/cmaj.1041203","article-title":"Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis","volume":"172","author":"Arrich","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.joca.2015.07.001_bib38","article-title":"Diacerein for osteoarthritis","volume":"2","author":"Fidelix","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.joca.2015.07.001_bib39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/1529-0131(199801)41:1<81::AID-ART11>3.0.CO;2-9","volume":"41","author":"Maheu","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2015.07.001_bib40","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.1780370413","article-title":"Diacerhein in the treatment of osteoarthritis of the hip","volume":"37","author":"Nguyen","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2015.07.001_bib41","doi-asserted-by":"crossref","first-page":"580","DOI":"10.7326\/0003-4819-146-8-200704170-00009","article-title":"Meta-analysis: chondroitin for osteoarthritis of the knee or hip","volume":"146","author":"Reichenbach","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.joca.2015.07.001_bib42","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/art.22371","article-title":"Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator","volume":"56","author":"Herrero-Beaumont","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2015.07.001_bib43","series-title":"Clinical Development Programs for Drugs, Devices and Biological Products Intended for the Treatment of OA","author":"FDA Draft Guidance","year":"1999"},{"key":"10.1016\/j.joca.2015.07.001_bib44","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1136\/ard.2005.037309","article-title":"Three year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study","volume":"64","author":"Bruyere","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.07.001_bib45","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00223-013-9781-z","article-title":"Changes in structure and symptoms in knee osteoarthritis and prediction of future knee replacement over 8 years","volume":"93","author":"Bruyere","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.joca.2015.07.001_bib46","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0889-857X(05)70079-X","article-title":"Plain radiography as an outcome measure in clinical trials involving patients with knee osteoarthritis","volume":"25","author":"Mazzuca","year":"1999","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.joca.2015.07.001_bib47","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1002\/art.21409","article-title":"Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs","volume":"52","author":"Brandt","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2015.07.001_bib48","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.joca.2009.01.007","article-title":"OARSI-OMERACT definition of relevant radiological progression in hip\/knee osteoarthritis","volume":"17","author":"Ornetti","year":"2009","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2015.07.001_bib49","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2012-202231","article-title":"Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial","volume":"72","author":"Reginster","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.07.001_bib50","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/art.23973","article-title":"The effect of glucosamine and\/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine\/chondroitin arthritis intervention trial","volume":"58","author":"Sawitzke","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2015.07.001_bib51","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/ard.2003.019703","article-title":"Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis","volume":"63","author":"Pham","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.07.001_bib52","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/annrheumdis-2012-202485","article-title":"Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study","volume":"73","author":"Maheu","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.07.001_bib53","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.20867","article-title":"Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial","volume":"52","author":"Michel","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2015.07.001_bib54","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.joca.2007.06.011","article-title":"Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials","volume":"16","author":"Bruyere","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2015.07.001_bib55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.berh.2014.01.007","article-title":"Biomarkers for osteoarthritis: current position and steps towards further validation","volume":"28","author":"Hunter","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458415012315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458415012315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:39:27Z","timestamp":1761017967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1063458415012315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1063458415012315"],"URL":"https:\/\/doi.org\/10.1016\/j.joca.2015.07.001","relation":{},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joca.2015.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}